DiagnoCure Inc. reported earnings results for the third quarter ended July 31, 2015. For the quarter, the company reported net loss of $274,005 or $0.01 per basic and diluted share compared to $504,105 or $0.01 per basic and diluted share a year ago. The net loss before non-cash elements decreased by 54%, from $406,853 for the third quarter of 2014 to $186,335 for the same period of 2015.

These decreases are attributable primarily to the reduction of operating expenses implemented in the first quarter of 2015. Total revenues for the third quarter of 2015 were $132,841 compared with $153,424 for the same period of 2014. Without taking into account the effect of the exchange rate variation, total revenues decrease by 16%, to $102,000 for the third quarter of 2015 compared with $121,000 for the same period of 2014.

This decrease is mainly attributable to a decrease in PCA3 European royalty revenues as compared to the same period in 2014.